280 related articles for article (PubMed ID: 15667536)
21. Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388.
Góra-Tybor J; Robak T
Acta Haematol Pol; 1993; 24(2):177-82. PubMed ID: 8103959
[TBL] [Abstract][Full Text] [Related]
22. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
[TBL] [Abstract][Full Text] [Related]
23. Chemoimmunotherapy of B 16 melanoma and P388 leukemia with cyclophosphamide and pyrimidinones.
Li LH; Johnson MA; Moeller RB; Wallace TL
Cancer Res; 1984 Jul; 44(7):2841-7. PubMed ID: 6722813
[TBL] [Abstract][Full Text] [Related]
24. N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin.
Israel M; Modest EJ; Frei E
Cancer Res; 1975 May; 35(5):1365-8. PubMed ID: 1054622
[TBL] [Abstract][Full Text] [Related]
25. Chemoimmunotherapy of L1210 leukemia with adriamycin, cyclophosphamide, and OK-432, and their effects on the generation of antitumor immunity.
Ujiie T
Jpn J Cancer Res; 1987 Jul; 78(7):737-47. PubMed ID: 3114200
[TBL] [Abstract][Full Text] [Related]
26. Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents.
Barret JM; Kruczynski A; Etiévant C; Hill BT
Cancer Chemother Pharmacol; 2002 Jun; 49(6):479-86. PubMed ID: 12107553
[TBL] [Abstract][Full Text] [Related]
27. Inability of amphotericin B(Fungizone) or of sodium deoxycholate to alter natural drug resistance or sensitivity of transplanted murine leukemias.
Ganu UK; Khandalekar DD; Gokhale SV
Indian J Physiol Pharmacol; 1984; 28(1):21-6. PubMed ID: 6490126
[TBL] [Abstract][Full Text] [Related]
28. Antileukemic effect of homo-aza-steroidal ester of [p-[bis(2-chloroethyl)amino]phenyl]acetic acid.
Wampler GL; Catsoulacos P
Cancer Treat Rep; 1977; 61(1):37-41. PubMed ID: 861962
[TBL] [Abstract][Full Text] [Related]
29. Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group.
Kalinka-Warzocha E; Wajs J; Lech-Maranda E; Ceglarek B; Holowiecki J; Federowicz I; Walewski J; Czyz J; Robak T; Warzocha K;
Cancer; 2008 Jul; 113(2):367-75. PubMed ID: 18470902
[TBL] [Abstract][Full Text] [Related]
30. Dexamethasone does not enhance antileukemic activity of cladribine in mice with leukemias L1210 and P388.
Robak T; Szmigielska A
Neoplasma; 2000; 47(3):168-71. PubMed ID: 11043840
[TBL] [Abstract][Full Text] [Related]
31. [In vitro evaluation of the chemosensitivity of an experimental murine leukemia rendered resistant in vivo to adriamycin].
Lepri E; Menconi E; Barzi AM
Boll Soc Ital Biol Sper; 1984 Jul; 60(7):1369-75. PubMed ID: 6477749
[TBL] [Abstract][Full Text] [Related]
32. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
33. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with a special emphasis on quinacrine.
Inaba M; Maruyama E
Cancer Res; 1988 Apr; 48(8):2064-7. PubMed ID: 3349478
[TBL] [Abstract][Full Text] [Related]
34. Effects of Dex-Verapamil on Doxorubicin cytotoxicity in P388 murine leukemia cells.
Noviello E; Allievi E; Russo P; Parodi S
Anticancer Drug Des; 1997 Jun; 12(4):261-76. PubMed ID: 9199659
[TBL] [Abstract][Full Text] [Related]
35. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
[TBL] [Abstract][Full Text] [Related]
36. Comparative study of sister chromatid exchange induction and antitumor effects by homo-aza-steroidal esters of [p-[bis(2-chloroethyl)amino]phenyl]butyric acid.
Camoutsis C; Catsoulacos D; Karayiann V; Papageorgiou A; Mourelatos D; Mioglou E; Kritsi Z; Nikolaropoulos S
Cancer Detect Prev; 2001; 25(6):558-64. PubMed ID: 12132876
[TBL] [Abstract][Full Text] [Related]
37. Cytogenetic and antineoplastic effects by newly synthesised steroidal alkylators in lymphocytic leukaemia P388 cells in vivo.
Mourelatos C; Kareli D; Dafa E; Argyraki M; Koutsourea A; Papakonstantinou I; Fousteris M; Pairas G; Nikolaropoulos S; Lialiaris TS
Mutat Res; 2012 Jul; 746(1):1-6. PubMed ID: 22464985
[TBL] [Abstract][Full Text] [Related]
38. Activity of 17 beta-hydroxy-3-aza-A-homo-4 alpha-androsten-4-one-p-N, N-bis(2-chloroethyl)aminophenoxyacetate (NSC-620480) in P388 leukemia. Activity of steroidal lactams in Ehrlich tumor.
Catsoulacos P; Pairas G
Methods Find Exp Clin Pharmacol; 1990 Sep; 12(7):501-5. PubMed ID: 2087151
[TBL] [Abstract][Full Text] [Related]
39. Effect of a delta 5-homo-aza-steroidal ester in P388 and L1210 murine leukemias.
Catsoulacos P; Camoutsis C; Wampler GL
Oncology; 1982; 39(1):59-60. PubMed ID: 7058047
[TBL] [Abstract][Full Text] [Related]
40. Potentiation of actinomycin D or adriamycin antitumor activity with DNA.
Marks TA; Venditti JM
Cancer Res; 1976 Feb; 36(2 Pt 1):496-504. PubMed ID: 1260747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
